Volume 82, Issue 3 pp. 330-337
Original Article

Cortical bone mineral density in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency

Diala El-Maouche

Diala El-Maouche

National Institute of Dental and Craniofacial Research, National Institutes of Health (NIH), Bethesda, MD, USA

National Institutes of Health (NIH) Clinical Center, Bethesda, MD, USA

Search for more papers by this author
Suzanne Collier

Suzanne Collier

National Institutes of Health (NIH) Clinical Center, Bethesda, MD, USA

Search for more papers by this author
Mala Prasad

Mala Prasad

Radiology and Imaging Sciences Department, Warren G. Magnuson Clinical Center, National Institutes of Health (NIH), Bethesda, MD, USA

Search for more papers by this author
James C. Reynolds

James C. Reynolds

Radiology and Imaging Sciences Department, Warren G. Magnuson Clinical Center, National Institutes of Health (NIH), Bethesda, MD, USA

Search for more papers by this author
Deborah P. Merke

Corresponding Author

Deborah P. Merke

National Institutes of Health (NIH) Clinical Center, Bethesda, MD, USA

Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health (NIH), Bethesda, MD, USA

Correspondence: Deborah P. Merke, National Institutes of Health Clinical Center, Building 10, Clinical Research Center, Room 1-2740, 10 Center Drive, Mail Stop Code 1932, Bethesda, MD 20892-1932, USA. Tel.: +301 496 0718; E-mail: [email protected]Search for more papers by this author
First published: 24 May 2014
Citations: 45

Summary

Background

Prior studies reveal that bone mineral density (BMD) in congenital adrenal hyperplasia (CAH) is mostly in the osteopaenic range and is associated with lifetime glucocorticoid dose. The forearm, a measure of cortical bone density, has not been evaluated.

Objective

We aimed to evaluate BMD at various sites, including the forearm, and the factors associated with low BMD in CAH patients.

Methods

Eighty CAH adults (47 classic, 33 nonclassic) underwent dual-energy-x-ray absorptiometry and laboratory and clinical evaluation. BMD Z-scores at the AP spine, total hip, femoral neck, forearm and whole body were examined in relation to phenotype, body mass index, current glucocorticoid dose, average 5-year glucocorticoid dose, vitamin D, 17-hydroxyprogesterone, androstenedione, testosterone, dehydroepiandrosterone and dehydroepiandrosterone sulphate (DHEAS).

Results

Reduced BMD (T-score <−1 at hip, spine, or forearm) was present in 52% and was more common in classic than nonclassic patients (= 0·005), with the greatest difference observed at the forearm (= 0·01). Patients with classic compared to nonclassic CAH, had higher 17-hydroxyprogesterone (= 0·005), lower DHEAS (= 0·0002) and higher non-traumatic fracture rate (P = 0·0005). In a multivariate analysis after adjusting for age, gender, height standard deviation, phenotype and cumulative glucocorticoid exposure, higher DHEAS was independently associated with higher BMD at the spine, radius and whole body.

Conclusion

Classic CAH patients have lower BMD than nonclassic patients, with the most affected area being the forearm. This first study of forearm BMD in CAH patients suggests that low DHEAS may be associated with weak cortical bone independent of glucocorticoid exposure.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.